Home › Companies › AGMB

Agomab Therapeutics

AGMB Rare disease Lead: Phase 2 1 Biotech Distilled article ↓

Immunology Respiratory Protein Small Molecule

Most recent annual filing: 2026-04-23

Pipeline (4 active programs)

ontunisertib

Small Molecule Target: ALK5, TGFβ

Fibrostenotic Crohn's Disease Phase 2

AGMB-447

Small Molecule Target: ALK5, TGFβ

Idiopathic Pulmonary Fibrosis Phase 1

AGMB-101

Protein Target: cMET, HGF

Undisclosed indication Preclinical

AGMB-102

Protein Target: cMET, HGF

Undisclosed indication Preclinical

Biotech Distilled coverage (1)

2026-06-15 Agomab Therapeutics (AGMB) — Scientific Deep Dive for Ontunisertib (AGMB-129), AGMB-447 and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.